SAN DIEGO, Dec. 16, 2019 /PRNewswire/ -- Decipher Biosciences, a commercial stage precision oncology company initially focused on urologic cancers, today announced that recent findings from a ...
SAN DIEGO, March 24, 2020 /PRNewswire/ -- Decipher Biosciences, a commercial-stage precision oncology company committed to improving patient care, initially focused on urologic cancers, today ...
The Decipher (GenomeDX Biosciences) test differentiates men at higher risk for prostate cancer metastasis after prostatectomy from those at lower risk and adds prognostic value in comparison with ...
DeCipher: A Novel ChatGPT-based Service for Web3 Developers, Enabling Precise Documentation Generation from Smart Contracts DeCipher leverages advanced AI models, ChatGPT3.5 and 4, specifically ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced new data demonstrating that a genomic signature derived from the company’s Decipher GRID database could help ...
Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients
Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of ...
Decipher test scores are independently associated with biopsy upgrades in men on active surveillance for Gleason grade group 1 prostate cancer. Higher Decipher scores on the initial test are ...
Bunzz PTE LTD, a Singapore-based tech company, is thrilled to announce the successful release of “DeCipher“, a revolutionary AI-powered tool designed to transform the process of generating smart ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results